0.00
—
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About ContraFect
Its shares trade under the ticker CFRXQ. It has been listed since 29 July 2014.
ContraFect Corp. is a clinical stage biotechnology company, which engages in the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. The company is headquartered in Yonkers, New York. The company went IPO on 2014-07-29. The firm is focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lead DLA product candidate, exebacase (CF-301), is used for the treatment of methicillin-resistant S. aureus (MRSA) bloodstream infections (bacteremia), including right-sided endocarditis, when used in addition to standard-of-care (SOC) anti-staphylococcal antibiotics in adult patients. Its CF-301 is being studied in an ongoing Phase Ib/II study in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci. Its other product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumanni, and has demonstrated potent in vivo activity against these pathogens.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 29 Jul 2014
- Employees
- 23
- Website
- contrafect.com ↗
Leadership
Pay as last reported
- Dr. Roger PomerantzChairman of the Board, President, Chief Executive Officer, since 2014$2.2m
- Dr. Steven GilmanVice Chairman of the Board, since 2015$160,544
- Mr. Michael MessingerChief Financial Officer$957,211
- Ms. Natalie BogdanosGeneral Counsel, Corporate Secretary, Data Protection Officer$844,896
- Dr. Sol BarerLead Independent Director, since 2012$176,044
- Dr. Lishan AklogIndependent Director$150,544
- Dr. Jane BarlowIndependent Director$155,544
- Mr. David LowIndependent Director$165,044
- Dr. Michael OttoIndependent Director$160,044
- Mr. Cary SucoffIndependent Director$155,544
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 42
- Environment
- 44
- Social
- 55
- Governance
- 29
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- ContraFect Corp employs 23 full-time staff in the Health Care sector.
- The company focuses on direct lytic agents for antibiotic-resistant infections.
- Exebacase targets methicillin-resistant S. aureus bloodstream infections in adult patients.
Weaknesses
- The firm has only 23 employees, limiting operational capacity significantly.
- ContraFect Corp is a clinical stage company with no revenue.
- The company relies on a single lead product candidate currently.
Opportunities
- Exebacase is studied for chronic prosthetic joint infections of the knee.
- CF-370 targets a range of gram-negative bacteria effectively.
- New medical modalities offer treatment for life-threatening infections globally.
Threats
- Antibiotic-resistant infections pose a significant challenge to treatment efficacy.
- Standard-of-care anti-staphylococcal antibiotics remain the primary treatment alternative.
- Competitors may develop similar direct lytic agents for infections.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.